You are here: Industry Insights > Novartis

News List

Amgen, Novartis, Banner Alzheimer's Institute Discontinue CNP520 Clinical Research americanpharmaceuticalreview
July 16, 2019
Amgen, Novartis, and Banner Alzheimer's Institute announced the collective decision to discontinue investigation of the BACE1 inhibitor CNP520 (umibecestat) in ...
Amgen, Novartis and Banner Discontinue CNP520 in AD contractpharma
July 15, 2019
An assessment of data identified worsening in some measures of cognitive function.
Mirati Announces Clinical Collaboration with Novartis americanpharmaceuticalreview
July 11, 2019
Mirati Therapeutics announced a clinical collaboration agreement with Novartis to evaluate the combination of MRTX849, Mirati's investigational KRAS G12C inhibitor and TNO155, Novartis' investigational SHP2 inhibitor, in patients with advanced solid tumor
Novartis Announces 26 Week Gender-Neutral Parental Leave expresspharma
July 04, 2019
The company will also offer coaching to associates going on leave for a seamless reintegration into the workplace when they resume work
Novartis acquires ophthalmic drug from Takeda for $3.4bn pharmaceutical-technology
July 04, 2019
Novartis has acquired ophthalmic solution Xiidra (lifitegrast) 5% from Takeda Pharmaceutical for an upfront cash payment of $3.4bn.
Can tiny Dova take on Novartis? With its 2nd Doptelet nod and a price cut, maybe so fiercepharma
July 04, 2019
In what one analyst team called Dova Pharmaceuticals’ “biggest catalyst to date,” the company won a second FDA nod for its platelet-boosting drug Doptelet, setting the stage for direct competition against Novartis and its still-growing blockbuster Promact
Novartis unloading sterile production facility to Lonza fiercepharma
July 04, 2019
Novartis, looking to the future, has been shedding some of its manufacturing operations from the past. Some from the recent past.
Takeda Completes Sale of Xiidra® to Novartis americanpharmaceuticalreview
July 03, 2019
Takeda announced the completion of its sale of its Xiidra® (lifitegrast ophthalmic solution) 5% product to Novartis for $3.4 billion upfront in cash and up to an additional $1.9 billion in potential milestone payments.
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio worldpharmanews
July 02, 2019
Novartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolio.
Lonza to Acquire Sterile Fill and Finish Facility from Novartis contractpharma
July 02, 2019
First facility for Lonza’s Drug Product Services to cover sterile manufacturing for clinical production and commercial launches.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 71 72 Next page